Oslo, 19 September 2023: EXACT Therapeutics AS will release the interim first
half 2023 results on Thursday 28 September 2023 at 08:00 (CEST).
 
A presentation of the first half year 2023 financials followed by a Q&A session
will be held on the same day 14:00-15:00 at Carnegie's offices at Aker Brygge,
Fjordalleen 16, and through a live webcast. The company expects to have the top
line clinical results of the dose-escalation study available and released by
this date, which will be included in the presentation. The presentation and the
Q&A session can be followed through a live webcast (Teams) or by physical
attendance. 
 
CEO, Per Walday, CFO, John M. Edminson and CMO, Amir Snapir will hold the
presentation.
 
Participants who want to participate in the live webcast or by physical
attendance are asked to send an email to john.edminson@exact-tx.com for a
separate invitation, which will be distributed 1 day prior to the meeting. It
will be possible to post or ask questions throughout the presentation.
 
The report for the first half year 2023 will be available on www.newsweb.no and
on the company's homepage www.exact-tx.com from 08:00 on Thursday, 28 September
2023.
 
About EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage Norwegian biopharmaceutical company
specializing in ultrasound-mediated drug delivery. Their proprietary Acoustic
Cluster Therapy (ACT®) platform follows a unique approach to targeted drug
enhancement, with the potential to significantly amplify the clinical utility of
a wide range of therapeutic agents across multiple indications, including
oncology and brain diseases.